JNJ 41443532

Drug Profile

JNJ 41443532

Alternative Names: JNJ-41443532

Latest Information Update: 03 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Developer Janssen Research & Development
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action CCR2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 18 Aug 2015 No recent reports on development identified - Phase-I for Type-2 diabetes mellitus (In volunteers) in Belgium (PO)
  • 10 Dec 2010 Phase-II clinical trials in Type-2 diabetes mellitus in USA (PO)
  • 29 Apr 2010 Phase-I clinical trials in Type-2 diabetes mellitus in Belgium (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top